Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jana, Karolova"'
Autor:
Pavel Klener, Marek Trneny, Eva Fronkova, Adela Berkova, Petra Vockova, Mariana Pacheco-Blanco, Kristina Forsterova, Karel Helman, Eva Pokorna, Diana Tuskova, Zuzana Zemanova, Karla Svobodova, Jan Soukup, Ondrej Havranek, Magdalena Klanova, Michael Svaton, Jana Karolova, Zuzana Nahacka, Ladislav Andera, Dana Prukova
Purpose:Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over)expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f5c886ce44042199a0881ea8008748
https://doi.org/10.1158/1078-0432.c.6528017
https://doi.org/10.1158/1078-0432.c.6528017
Autor:
Pavel Klener, Marek Trneny, Eva Fronkova, Adela Berkova, Petra Vockova, Mariana Pacheco-Blanco, Kristina Forsterova, Karel Helman, Eva Pokorna, Diana Tuskova, Zuzana Zemanova, Karla Svobodova, Jan Soukup, Ondrej Havranek, Magdalena Klanova, Michael Svaton, Jana Karolova, Zuzana Nahacka, Ladislav Andera, Dana Prukova
Supplemental Figure 1. Next-generation sequencing of PDXs and primary MCL cells Supplemental Figure 2. IHC analysis of primary MCL samples and murine xenografts Supplemental Figure 3. Array comparative genomic hybridization of 24 primary MCL samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9434da02e49e1026da548d1f72ae836
https://doi.org/10.1158/1078-0432.22471799
https://doi.org/10.1158/1078-0432.22471799
Autor:
Graham Packham, Pavel Klener, Lloyd Mackenzie, Jennifer Cross, Andrew J. Steele, Francesco Forconi, Mark Cragg, Freda K. Stevenson, Curtis Harwig, Jeremy Pettigrew, Georg Lenz, Chris T. Williamson, Laura Karydis, Nicola J. Weston-Bell, Karel Helman, Michael Svaton, Jana Karolova, Matthew J. Carter, Yohannes Gebreselassie, Johanna Richter, Lindsay D. Smith, Beatriz Valle-Argos, Elizabeth A. Lemm
Supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::067d77f6406b11ba2ff53f0855ef08b2
https://doi.org/10.1158/1078-0432.22478181
https://doi.org/10.1158/1078-0432.22478181
Publikováno v:
Vaccines, Vol 8, Iss 4, p 708 (2020)
Non-Hodgkin lymphomas (NHLs) are lymphoid malignancies of B- or T-cell origin. Despite great advances in treatment options and significant improvement of survival parameters, a large part of NHL patients either present with a chemotherapy-refractory
Externí odkaz:
https://doaj.org/article/5ef409b4224a4d8798d38adf9e4c8e03
Autor:
Jana Karolova, Dmitry Kazantsev, Michael Svaton, Liliana Tušková, Kristina Forsterova, Diana Malarikova, Katerina Benesova, Tomáš Heizer, Alexandra Dolníková, Magdalena Klanova, Eva Fronkova, Marek Trněný, Pavel Klener
Publikováno v:
Blood. 140:6409-6410
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2424eabb29be4ff758c84d2c79669fbf
https://doi.org/10.1182/blood-2022-166069
https://doi.org/10.1182/blood-2022-166069
Autor:
Michael Svaton, Zuzana Zemanova, Marek Trneny, Zuzana Nahacka, Magdalena Klanova, Jan Soukup, Mariana Pacheco-Blanco, Dana Prukova, Kristina Forsterova, Eva Fronkova, Jana Karolova, Karel Helman, Ladislav Andera, Pavel Klener, Karla Svobodova, Eva Pokorná, Ondrej Havranek, Petra Vockova, Adela Berkova, Diana Tuskova
Publikováno v:
Clinical Cancer Research. 25:4455-4465
Purpose: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over)expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6df51da911e3b076be45522ead8d4b6
https://doi.org/10.1158/1078-0432.ccr-18-3275
https://doi.org/10.1158/1078-0432.ccr-18-3275
Autor:
Magdalena, Klanova, Dmitry, Kazantsev, Eva, Pokorna, Tomas, Zikmund, Jana, Karolova, Matej, Behounek, Nicol, Renesova, Dana, Sovilj, Cristina D, Kelemen, Karel, Helman, Radek, Jaksa, Ondrej, Havranek, Ladislav, Andera, Marek, Trneny, Pavel, Klener
Publikováno v:
Mol. Cancer Ther. 21, 89-99 (2021)
The pro-survival MCL1 protein is overexpressed in many cancers, including B-cell non-Hodgkin lymphomas (B-NHL). S63845 is a highly specific inhibitor of MCL1. We analyzed mechanisms of sensitivity/resistance to S63845 in preclinical models of diffuse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b5042a29e167a06bd6977db7790bcb47
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=63422
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=63422
Autor:
Pavel Klener, Michal Pechar, Luděk Šefc, Eliška Böhmová, Petra Vockova, Jana Karolova, Jan Pankrác, Robert Pola, Tomáš Etrych, Eva Pokorná, Marek Trněný
Publikováno v:
SSRN Electronic Journal.
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (B-NHL) with chronically relapsing clinical course. Implementation of cytarabine (araC) into induction and salvage regimen became standard of care for majority of MCL patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f46b653fc509bbb6b09ce4a795bfa4a8
https://doi.org/10.2139/ssrn.3684928
https://doi.org/10.2139/ssrn.3684928
Autor:
Johanna Richter, Jana Karolova, Yohannes Gebreselassie, Georg Lenz, Chris T. Williamson, Mark S. Cragg, Michael Svaton, Beatriz Valle-Argos, Lindsay D. Smith, Elizabeth Lemm, Nicola J. Weston-Bell, Graham Packham, Laura I. Karydis, Andrew J. Steele, Curtis Harwig, Karel Helman, Freda K. Stevenson, Pavel Klener, Matthew J. Carter, Jennifer Cross, Francesco Forconi, Lloyd F Mackenzie, Jeremy D Pettigrew
Publikováno v:
Clin Cancer Res
Purpose:PI3K signaling is a common feature of B-cell neoplasms, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and PI3K inhibitors have been introduced into the clinic. However, there remains a clear need to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e14b2de6e33034fe5f7f6794dee808d8
https://europepmc.org/articles/PMC7124891/
https://europepmc.org/articles/PMC7124891/
Autor:
Dana, Prukova, Ladislav, Andera, Zuzana, Nahacka, Jana, Karolova, Michael, Svaton, Magdalena, Klanova, Ondrej, Havranek, Jan, Soukup, Karla, Svobodova, Zuzana, Zemanova, Diana, Tuskova, Eva, Pokorna, Karel, Helman, Kristina, Forsterova, Mariana, Pacheco-Blanco, Petra, Vockova, Adela, Berkova, Eva, Fronkova, Marek, Trneny, Pavel, Klener
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(14)
Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell non-Hodgkin lymphomas characterized by (over)expression of BCL2. A BCL2-targeting drug, venetoclax, has promising anticancer activity in MCL. We analyzed molecular mechanisms of venetoclax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9f316d76c3a89a94e03d174ff45ed1f4
https://pubmed.ncbi.nlm.nih.gov/31004002
https://pubmed.ncbi.nlm.nih.gov/31004002